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Neuropeptides are found in manymammalian CNS neurons where they play key roles in modulating neuronal
activity. In contrast to amino acid transmitter release at the synapse, neuropeptide release is not restricted to
the synaptic specialization, and after release, a neuropeptide may diffuse some distance to exert its action
through a G protein-coupled receptor. Some neuropeptides such as hypocretin/orexin are synthesized
only in single regions of the brain, and the neurons releasing these peptides probably have similar functional
roles. Other peptides such as neuropeptide Y (NPY) are synthesized throughout the brain, and neurons that
synthesize the peptide in one region have no anatomical or functional connection with NPY neurons in other
brain regions. Here, I review converging data revealing a complex interaction between slow-acting neuromo-
dulator peptides and fast-acting amino acid transmitters in the control of energy homeostasis, drug addic-
tion, mood and motivation, sleep-wake states, and neuroendocrine regulation.Just as there are multiple perceptions for the proverbial blind
men as to what an elephant is, there are numerous perspectives
one can adopt to view neuropeptide modulation in the CNS.
Here, I take the view that neuropeptide modulation in the CNS
is inextricably linked with fast amino acid GABA and glutamate
signaling. Many other viable perspectives exist and are not
mutually exclusive. I have used a few examples of peptide
secretion and actions which may be representative of many
brain regions not discussed herein; many of the examples
used here are from the hypothalamus, the part of the brain
where neuropeptides have been most thoroughly studied.
Many important neuropeptides are not included in the review.
Although the focus here is on neuropeptides, some of the mech-
anisms of release and many of the mechanisms of response to
neuropeptides may generalize to other neuromodulators in the
brain, including the catecholamines, serotonin, adenosine, en-
docannabinoids, and neurotrophic factors. Neuropeptides can
exert direct effects on neuronal physiology within seconds to
minutes, and can also modulate gene expression over the
course of hours to days; the focus here is on the direct neuro-
physiological actions.
The nomenclature of neuropeptides can initially be confusing.
Names of CNS neuropeptides often give a historical perspec-
tive indicating what the peptide-pioneers initially discovered
as the putative function. Since many neuropeptides were
discovered in the context of regulation of hormone release,
neuropeptide names may bear that functional link. True to its
name, somatostatin released into the portal blood supply of
the median eminence from nearby hypothalamic neurons can
decrease growth hormone secretion from the pituitary gland;
on the other hand, the somatostatin-synthesizing neurons in
the cortex and hippocampus have no functional relation to
hormone regulation. The same is true for thyrotropin-releasing
hormone in thalamic neurons, and vasopressin- and gastrin-
releasing peptide in circadian clock neurons of the suprachias-
matic nucleus where the neuropeptide names have no bearing
on their local function.98 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.Where Do Peptides Act?
Despite strong evidence showing substantive functional roles for
many neuropeptides, at the cellular level a number of mysteries
remain. Even seemingly straightforward questions can be
complicated, such as: how far from a neuronal neuropeptide
release site does a peptide act? For the amino acid neurotrans-
mitters GABA, glycine, and glutamate, release occurs to a large
degree at a presynaptic active zone, the transmitter diffuses
a few tens of nanometers, activates receptors on the postsyn-
aptic neuron, and then the transmitter is rapidly degraded or
transported intracellularly. Amino acid transmitters act rapidly
at ionotropic receptors and at very discrete and spatially adja-
cent synaptic sites. Neuropeptides, in contrast, may be released
from many additional release sites not restricted to the synaptic
specialization, raising the question of where they act. For
example, in classic work on the frog sympathetic ganglia, a
gonadotropin-releasing hormone (GnRH)-like peptide was
released by preganglion axons and acted on cells some microns
away from the release site (Jan and Jan, 1982). Even in the case
of nonsynaptic release, a neuropeptide could still act on cells
that are postsynaptic to the axon that releases it. For instance,
GABAergic neuropeptide Y (NPY) cells of the arcuate nucleus
make synaptic contact with other nearby arcuate nucleus
neurons that synthesize proopiomelanocortins (POMC); NPY
hyperpolarizes the POMC neurons (Cowley et al., 2001), and
therefore even though NPY may not be released synaptically, it
can still exert an inhibitory effect on the cell postsynaptic to its
parent axon.
A second possibility that has received considerable attention
is that the peptide can diffuse long distances to act far from
the release site. Very long distance signaling has been found
for a number of neuroactive peptides/proteins. For instance, lep-
tin from adipose tissue, ghrelin from the stomach, and insulin
from the pancreas are released a long distance from the brain
but act on receptors within the CNS as signals of energy homeo-
stasis. The blood brain barrier may prohibit entrance into the
brain for many blood borne peptides; on the other hand, some
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nucleus may maintain a weak blood brain barrier which permits
blood borne signals to enter the brain. Enhanced transport
mechanisms may also exist for facilitating movement of some
peptides into the brain. Long-distance signaling within the brain
has been called volume transmission, and there is a substantial
body of literature addressing this (Fuxe et al., 2005, 2007; Jans-
son et al., 2002). Consistent with long distance diffusion, neuro-
peptide receptors aided by G protein amplification tend to be
sensitive to low nanomolar concentrations of peptide; this
compares to the substantially less sensitive ionotropic amino
acid receptors that respond to micromolar quantities of GABA
or glutamate. Furthermore, some peptides have been suggested
to maintain a long extracellular half-life (Ludwig and Leng, 2006),
thereby maintaining activity during the temporal window
required for diffusion.
In many parts of the brain, the expression patterns of peptide-
containing processes and the homologous peptide receptors
overlap, consistent with a local action of the neuropeptide. But
in a large number of CNS loci, the anatomical expression of a
particular peptide and its receptors may be in completely
different regions of the brain, as noted in the extensive review
of such anatomical mismatches by Herkenham (1987). This
peptide-receptor mismatch could be simply a nonfunctional
throwback to some partial preservation of an interaction that
was important in the evolutionary past but is no longer relevant.
Alternately, for peptides such as oxytocin, there may be massive
release due to the simultaneous activation of a majority of
oxytocin neurons within the brain; this can raise the extracellular
oxytocin in the area of the supraoptic nucleus to a level 100-fold
greater than circulating oxytocin (Ludwig and Leng, 2006), allow-
ing diffusion of a higher concentration of peptide to activate
oxytocin receptors at more distant sites than would be possible
with asynchronous firing.
Arguing against long distance release and response as
a general rule is the fact that a number of neuropeptides, for
instance, NPY, dynorphin, or somatostatin, are synthesized
and released by many unrelated groups of neurons in different
regions of the brain. Any specific role of the peptide relevant to
the releasing neuron would be negated if the same peptide
from other brain regions was diffusing long distances. Further-
more, peptidases actively break down peptides extracellularly,
reducing the effective distance an active peptide may diffuse.
Depending on the size, presence of disulfide bonds which
increase peptide half-life, amidation, and chemical confirmation
of the peptide, peptide half-lives can vary.
Administration of a particular peptide or other modulator into
a receptor-rich region of the brain lacking in that particular
peptide can generate very selective functional responses, sug-
gesting a functional plausibility to volume transmission. How-
ever, neuropeptide receptors simply respond to peptide, and
even if the response is specific for a particular brain region or
circuit, it may be simply a response of selective circuit activation
or inhibition that may not normally occur. A more convincing
strategy to show that long distance neuropeptide diffusion may
play a functional role would be the use of a receptor antagonist
in a region lacking specific peptidergic inputs to show the oppo-
site effect of peptide injection; but even the receptor antagoniststrategy can be complicated, as some receptor antagonists may
act as inverse agonists, reducing a constitutively active receptor
to a level below a normal partially-active state.
For the majority of axons in the CNS that release neuropep-
tides, I favor a third local diffusionhypothesis- that neuropeptides
releasedbymost neuronsact locally on cells near the releasesite,
with a distance of action of a few microns. Thus, a peptide’s
action would be on its synaptic partners (even if the peptide is
not released at the presynaptic specialization) and on immedi-
ately adjacent cells. In part this perspective is based on the low
frequency of dense core vesicles in most CNS axons and the
hours it would take to replenish released peptides from sites of
synthesis in the cell body, making it difficult to achieve a sub-
stantial extracellular concentration of neuropeptide needed for
a long-distance effect. In this context, the relatively slow replen-
ishment of neuropeptide modulators may differ from catechol-
amine neuromodulators that can be synthesized rapidly within
axon terminals to support ongoing release. Furthermore, as
determinedwith ultrastructural analysis, a complex systemof as-
trocytic processes surrounds many axodendritic synaptic com-
plexes and tends to attenuate long-distance transmitter diffusion
from many release sites (Figure 1; Peters et al., 1991), thereby
impeding actions of peptides at far-away targets, and maintain-
ing a higher local extracellular concentration of the peptide.
Peters et al. credit Ramon y Cajal with favoring the concept that
a central function for gliawas isolation of neuronalmicrodomains.
That peptides released by most neurons may act within a few
microns of the release site does not negate the fact that some
peptides can be released in large quantities and can act at longer
distances. This may be the exception rather than the rule. For
instance, considering the multiple subtypes of highly specialized
NPY or somatostatin interneurons in the hippocampus or cortex,
coupled with the multiple peptide responses reported in nearby
cells and the highly specialized functions of different nearby
interneurons, often with restricted functional microdomains
(Freund and Buzsa´ki, 1996; Bacci et al., 2002; Klausberger
et al., 2003), it seems most likely that released peptides here
act primarily on nearby receptive partners.
Consistent with the local diffusion perspective are findings
related to peptides such as pigment dispersing factor (PDF)
which plays a key role in regulating circadian rhythms of inverte-
brates (Im and Taghert, 2010; Zhang et al., 2010). Although cells
that release PDF project to several regions of the Drosophila
brain, the response of the releasing cells to PDF appears to be
critical for some aspects of circadian function. Secreted PDF
acts on PDF autoreceptors expressed by the releasing lateral-
ventral pacemaker neurons to regulate the time of day during
which behavioral activity occurs (Choi et al., 2012; Taghert and
Nitabach, 2012, this issue of Neuron).
G Protein-Coupled Receptors
Most neuropeptides act by binding to a seven-transmembrane
domain G protein-coupled receptor (GPCR). Many hundreds of
these receptors have been identified and their normal ligand is
known; the ligands for a number of orphan GPCRs have not yet
been identified (see Civelli, 2012, this issue of Neuron). Binding
to the GPCR induces a conformational change in the receptor,
leading to activation of intracellular G proteins. Many G proteinsNeuron 76, October 4, 2012 ª2012 Elsevier Inc. 99
Figure 1. Astrocytes Isolate Synaptic Complexes
(A) Astrocytic processes (Ast.Proc.) surround presynaptic axons in contact
with central dendrite (DEN). Short arrows indicate SIG, silver intensified im-
munogold, long arrow showsDCV, dense core vesicle. Horizontal arrows show
astrocytic process surrounding synaptic complex. From van den Pol (1988).
(B) Three boutons contact a central dendrite (DEN). Two GABA boutons are
labeledwith immunogold, a thirdboutonmakesanasymmetrical synapse (A.S.)
typical of glutamate synapses. The synaptic complex is surrounded by several
layers of astrocytic processes (Ast.Proc.), indicated by horizontal arrows.
Width of micrograph, (A) 1.1 mm, (B) 1 mm.
100 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.
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Gg. Activation results in an exchange of GDP for GTP at the G
protein’s a subunit and the dissociation of the G proteins from
the GPCR. Peptide signaling is then amplified by the induction
of multiple intracellular signaling pathways that may involve ad-
enylyl cyclase, cAMP, MAPK/ERK, PKA, and phosphorylation
of a number of target proteins. Monomeric G proteins may also
play a role in modulating some ion channels and actions of
peptides (Murray and O’Connor, 2004; Vo¨gler et al., 2008; Tha-
pliyal et al., 2008), and multiple G protein/effectors have been
described for some neuropeptides, for instance GnRH (Gardner
and Pawson, 2009). The actions of neuropeptides onGPCRs can
also be modulated at the receptor or effector level; for instance,
members of the RGS (regulator of G protein signaling) family of
proteins can accelerate activation or deactivation of G proteins
and may alter receptor-effector coupling (Chuang et al., 1998;
Doupnik et al., 2004; Laboue`be et al., 2007; Xie and Martemya-
nov, 2011). The literature on GPCRs is too voluminous to
examine here, but has been addressed in some recent reviews
(Rosenbaum et al., 2009; Hazell et al., 2012).
Peptide receptors are found heterogeneously distributed
throughout the brain, and can be expressed on cell bodies,
dendrites, and axon terminals. Some peptides, for instance
NPY, activate multiple different receptors expressed by target
neurons, whereas others appear to act primarily on a single
receptor, for instance kisspeptin acts primarily on GPR54. Our
understanding of peptide receptor subcellular localization has
lagged behind that of amino acid receptor localization, in part
due to questionable specificity of some peptide receptor anti-
sera. Perhaps the clearest picture that emerges of a class of
neuronal GPCRs is for metabotropic glutamate receptors
(mGluRs). These function similarly to neuropeptide GPCRs but
are activated by glutamate and can act in an excitatory or inhib-
itory manner. Subcellular localization of mGluRs may provide
some insight into the potential localization of neuropeptide
GPCRs. Eight different mGluRs have been identified and, inter-
estingly, are expressed in different regions of different neurons.
mGluR7, for instance, is often found at the presynaptic active
zone (Schoepp, 2001) and mGluR4, -7a, and -8a are found on
the presynaptic active zone of inhibitory axons, and only those
innervating other GABA interneurons but not those innervating
excitatory pyramidal cells (Kogo et al., 2004). mGluR1a is found
on the postsynaptic membrane at the periphery of the synapse
active zone (Baude et al., 1993); other mGluRs tend to be either
pre- or postsynaptic, depending on the expressing neuron and
mGluR subtype (Bradley et al., 1996). Future experiments on
the ultrastructural localization of neuropeptide receptors may
show similar sites of expression at specific regions of the plasma
membrane.
Which Neurons Contain Neuropeptides?
The classic view that neuropeptide-containing neurons repre-
sented an unusual type of neuron is giving way to the perspective
that many, perhaps most neurons in the brain, probably contain
some neuropeptide(s) or other neuromodulator in addition to
fast-acting amino acid neurotransmitters. In an examination of
individual sections containing synaptic boutons with electron
microscopy, with the boutons fixed to preserve the dense core
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cles, others contained clear and DCVs. However, serial ultrathin
section reconstruction of GABA-immunogold-labeled presyn-
aptic boutons from the paraventricular nucleus demonstrated
that every bouton contained at least a few dense core vesicles,
suggesting that in addition to a fast amino acid transmitter,
most if not all GABAergic axons here also contained some neu-
romodulator (Decavel and van den Pol, 1990). Release and
actions of these neuromodulators remains to be demonstrated.
Furthermore, because the axons studied contained GABAwhich
is not found inmagnocellular neurons, the profiles could not arise
from the local oxytocin or vasopressin neurosecretory cells.
Similarly, presynaptic boutons showing no immunogold GABA
labeling, many of which were probably glutamatergic, also
showed a similar frequency of DCVs in boutons, interspersed
with small clear vesicles. A complication to the detection of
DCVs with electron microscopy is that the dense core can be
lost by suboptimal fixation pH, duration, chemistry, and osmotic
pressure (Morris and Cannata, 1973), complicating detection in
some studies and biasing results toward a false-negative lack
of detectable DCVs.
A related question is whether all peptidergic axons also
contain a fast amino acid transmitter. Most evidence, including
that based on immunocytochemistry, calcium digital imaging,
and electrophysiology supports the perspective that the great
majority of peptidergic cells also employ fast amino acid trans-
mitters (van den Pol, 1991, 2003; van den Pol et al., 1990; van
den Pol and Trombley, 1993; Freund and Buzsa´ki, 1996).
Whereas hypothalamic neurons have long been recognized as
utilizing a large number of peptides, other regions of the brain are
now being seen as not substantively different in this regard. For
instance, in the hippocampus, a region with a rich history in the
study of fast GABA and glutamate transmission, a plethora of
neuropeptides are synthesized, particularly by GABAergic in-
hibitory interneurons, including neuropeptide Y, somatostatin,
vasoactive intestinal polypeptide, cholecystokinin, dynorphin,
enkephalin, neurokinin B, and substance P (Acsa´dy et al., 1996,
2000; Billova et al., 2007; Antonucci et al., 2012; Dun et al.,
1994; Bering et al., 1997; Freund and Buzsa´ki, 1996). Hippo-
campal pyramidal cells, often used as a primary model for
the study of glutamatergic neurons, are reported to express
peptides, for instancecholecystokinin (Wyethet al., 2012), partic-
ularly inmodels of brain disease such as epilepsy. Froman evolu-
tionary perspective, peptide synthesis in invertebrates may give
us clues as to the parallel in vertebrates. In Aplysia, every identi-
fied motorneuron was found to contain one or more of a number
of different peptide modulators (Church and Lloyd, 1991).
Neuropeptide Release
Scientists have a keen insight into the temporal sequence and
many of the molecules involved in the release of fast neurotrans-
mitters at presynaptic specializations (Su¨dhof, 2012). Release of
neuropeptides, mostly from nonsynaptic sites, has received
considerably less attention than fast transmitter release; neuro-
peptide release from dense core vesicles (DCVs) may require
a unique set of proteins that regulate transport and release
(Sieburth et al., 2005, 2007). Mammalian neuropeptide release
has been most thoroughly investigated in the neurohypophysiswhere axons arising frommagnocellular neurons of the hypotha-
lamic paraventricular and supraoptic nuclei converge to release
vasopressin or oxytocin into the vascular system. Vasopressin
plays a key role in water homeostasis and water reabsorption
in the kidney, and oxytocin acts to evoke milk release during
lactation. The neurohypophysis provides a good model to study
release, as it contains a high density of large axon terminals filled
with large (180–200 nm diameter) dense core neurosecretory
vesicles, providing a relatively high and measurable amount of
peptide release. Classical work here has shown that the amount
of neuropeptide released per spike increases with spike fre-
quency up to a point (Dreifuss et al., 1971; Gainer et al., 1986)
and that spike bursts followed by intervals of silence are partic-
ularly effective at releasing oxytocin or vasopressin (Dutton and
Dyball, 1979; Bicknell and Leng, 1981; Cazalis et al., 1985). A
mechanism that has been reported to underlie this enhanced-
release phenomenon is the increase in cytoplasmic calcium in
axon terminals induced by spike bursts which may be a key to
the enhanced probability of DCV exocytosis (Bondy et al.,
1987; Jackson et al., 1991; Muschol and Salzberg, 2000).
Although the neurohypophysis provides a useful model for
studying neuropeptide release, there are some serious differ-
ences between peptide release from large neurohypophyseal
boutons filled with large neurosecretory vesicles and peptide
release from the more common small axon terminals that may
possess medium size (100 nm diameter) neuropeptide-contain-
ing DCVs; large DCVs have been estimated to contain 60,000
(Dreifuss, 1975) or 85,000 (Nordmann and Morris, 1984) mole-
cules of oxytocin or vasopressin. The volume of the medium
size DCVs in most neurons is roughly about 1/8 of the volume
of the large DCV inmagnocellular neurons, suggesting a similarly
reduced peptide content (Figure 2). Most axons that release
neuropeptides contain only a small number of DCVs that show
no preferential localization near presynaptic specializations, in
contrast to glutamate- or GABA-containing small clear vesicles
that tend to congregate in the active zone near the synaptic
specialization (Figures 2 and 3). Unlike the small clear vesicles
that can be refilledwith amino acid transmitter by vesicular trans-
porters locally within the axonal bouton, neuropeptides are
synthesized on the rough endoplasmic reticulum, and loaded
into DCVs that are generated in the Golgi apparatus of the cell
body, and DCVs must be transported down long thin axons for
release at sites distant from the cell body. The relatively small
number of DCVs in axon terminals of most neurons suggests
that neuropeptide release from boutons in the CNS is under
considerably different spatial and temporal constraints than
release from the neurohypophysis. If the small number of
DCVs in a single CNS bouton undergo exocytosis, it may be at
least several hours before replenishment.
Invertebrate neurons have proven useful for the study of
vesicle transport and release (Church et al., 1993; Whim and
Lloyd, 1992). Recent imaging evidence in invertebrate neurons
suggests that neuropeptide-containing DCVs are transported
in a seemingly inefficient manner, and shuttle back and forth
between the cell body and distal axon terminal. These DCVs
move in an anterograde direction onmicrotubules with themotor
kinesin-3 (Barkus et al., 2008), and then switch to dynein for
a ride in the retrograde direction back to the axon initial segmentNeuron 76, October 4, 2012 ª2012 Elsevier Inc. 101
Figure 2. Two Axons Make Symmetrical-Type
Synaptic Contact with a Magnocellular Neuron
The presynaptic axons contain a few dense core vesicles
(DCV, arrowheads) and many small clear synaptic vesicles
(SV). In the postsynaptic neuron, a large dense core vesicle
(LDCV) is shown by long arrow. Width of micrograph, 4 mm.
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of DCVs moving into boutons during each trip (Wong et al.,
2012). In mammalian trigeminal ganglion neurons in vitro,
neuronal stimulation reduced anterograde velocity of DCVs,
and increased DCV pausing. As determined with pHluorin,
DCV membrane fusion and release occurred throughout the
axon and in axonal growth cones (Sobota et al., 2010).
A question that often arises when confronted with a peptide-
immunoreactive axon in apparent contact with another cell is
whether the axon makes a synapse with its putative partner,
theoretically therefore increasing the potential role of the
peptide. But maybe it is irrelevant if the immunoreactive axon
makes that synapse if peptides are released at nonsynaptic sites
and generally diffuse a few microns to activate nearby cells.
Why is peptide release difficult to study? Much of what we
know about fast transmitter release arises from the electrophys-
iological response to the released transmitter. Glutamate and
GABA both generate a very rapid ms response at the postsyn-
aptic specialization that can be easily detected as a shift in
voltage or current recorded from the postsynaptic neuron. In
contrast to the fast amino acid transmitters, as noted above,
the amount of neuropeptide released by a single bouton in the
CNS may be small, but even more importantly, the response of
receptive cells is relatively slow, on the order of many seconds
to minutes, making it difficult to correlate peptide release with
a response, and difficult to use quantal analysis of single or
multiple exocytotic events. Additionally, the rise time of a gluta-
mate- or GABA- mediated synaptic event is relatively fast, facil-
itating the segregation of individual events, whereas the rise time
for a neuromodulator is much slower. Finally, whereas a single
spike may release GABA or glutamate, peptide release may
require a higher level of activity, further confounding the study
of stimulus-response relationships. Capacitance recordings
have proven useful to study fusion of large DCVs and small102 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.clear vesicles in magnocellular axon terminals of
isolated neurohypophyses (Klyachko and Jackson,
2002) and in isolated magnocellular neuron cell
bodies (de Kock et al., 2003).
Peptides can be genetically labeled with a fluo-
rescent reporter such as GFP and examined micro-
scopically, assuming controls are used to ensure
that the reporter does not alter peptide transport
and release (Lang et al., 1997; Burke et al., 1997).
Release of fast transmitters has been studied with
lipophilic dyes such as FM1-43 to detect dye inter-
nalization upon vesicle fusion (Ryan and Smith,
1995) and with a number of interesting genetically
encoded agents, for instance pHluorin, a GFP
variant with pH sensitivity (Pan and Ryan, 2012;
Ariel and Ryan, 2010; Kim and Ryan, 2010), butthese approaches have been used only to a limited degree in
the study of peptide release from boutons in the CNS (e.g., Fuen-
zalida et al., 2011).
One promising approach in the mammalian CNS is the use of
the invertebrate neuropeptide FMRF that directly opens an ion
channel resulting in an inward Na+ current, independent of G
protein coupling (Lingueglia et al., 1995). The FMRF peptide
and its receptor can be expressed in mammalian cells to study
fast responses to released peptide (Whim and Moss, 2001).
This FMRF approach has been employed to study neuropeptide
release from secretory endocrine cells, including pancreatic beta
cells (Whim, 2011) and adrenal chromaffin cells where co-
release of neuropeptide and catecholamines from single vesicles
was reported (Whim, 2006).
Another dimension of neuropeptide release is whether it is
constitutive (ongoing) or actively regulated. Ongoing release
may result in desensitization of receptors, and a decrease in
response amplitude, or it may result in a chronically active
receptor. Different responses have been found with slow and
fast release of brain derived neurotrophic factor (BDNF). Acute
activation by BDNF of the TrkB receptor resulted in developing
hippocampal neuron neurite elongation, whereas sustained acti-
vation was more likely to initiate neurite branching, and the two
modes of release also differentially regulated expression of
Homer1 and Arc (Ji et al., 2010).
Dendritic Release of Neuropeptides
Peptides may be released locally by the somatodendritic com-
plex. Based on ultrastructural analysis of omega membrane-
fusion/release figures in fixed mammalian supraoptic nucleus
after high K+ or calcium ionophore A23187 stimulation, sugges-
tive evidence of neuropeptide exocytosis was found occasion-
ally at the presynaptic and perisynaptic membrane, but more
often independent of synaptic specializations, and was found
Figure 3. Comparison of Fast Amino Acid Synaptic Transmission (Left) and Slower Neuropeptide Transmission (Right)
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(Morris and Pow, 1991). Neuropeptide release from the somato-
dendritic complex of magnocellular neurons may provide a
unique insight into release mechanisms and peptide signaling
in general. Again, the neurosecretory cells of the supraoptic
nucleus of the hypothalamus (Figure 4) provide a model system
in which to study dendritic release. The model is aided by
the high level of neuropeptide synthesized by magnocellular
neurons, the presence of a large number of large peptide-
containing DCVs in the dendrites, and key to the interpretation
of many of the results, the probable absence of local axon
terminals originating from magnocellular neurosecretory cells.
Magnocellular axons project primarily to non-synaptic terminals
in the neurohypophysis. In the paraventricular nucleus but not in
the supraoptic nucleus, parvocellular neurons also synthesize
oxytocin and vasopressin; axons from these parvocellular
neurons do not target the neurohypophysis, but instead make
synaptic contact with other CNS neurons in the brain and spinal
cord (Hosoya and Matsushita, 1979; Sawchenko and Swanson,
1982; Swanson and Kuypers, 1980).
Increases in action potential frequency generally enhance
release of neuropeptides from both axons and dendrites. A key
ion in release of both fast amino acid transmitters and peptides
is calcium; peptide release may require a greater increase in
cytoplasmic calcium, and possibly greater neuronal activity,
than needed for amino acid secretion (Tallent, 2008). Depolariza-
tion of the membrane potential activates voltage-gated calciumchannels, leading to calcium influx through the plasma
membrane, and initiation of vesicle release. Several lines of evi-
dence suggest the intriguing possibility that dendritic release
may be regulated in a manner independent from axonal release
under some circumstances. In part, differences in release may
be dependent on different sets of ion channels in axons and
dendrites. For instance, different calcium channels may underlie
dynorphin release from hippocampal dendrites and axons;
activation of L-type calcium channels enhanced release from
dendrites, but not axons (Simmons et al., 1995). Depolariza-
tion-mediated oxytocin release from supraoptic neuron den-
drites was dependent primarily on N-type calcium channels
and to a lesser extent, P/Q channels; other calcium channels
played no substantive role in mature oxytocin neurons (Tobin
et al., 2011; Hirasawa et al., 2001). In parallel, calcium channel-
independent mechanisms differ between axons and cell body;
the endoplasmic reticulum plays a role in calcium regulation/
peptide release from the oxytocin cell body but does not appear
to play a substantive role in the axon terminal. Differences
between axon terminals and cell bodies may also be found in
systems that reduce calcium, including mitochondria, plasma
membrane calcium pumps, and sodium/calcium exchangers
(Dayanithi et al., 2012). Finally, ATP coreleased from magnocel-
lular neurons exerts different feedback effects on axon terminals
and cell bodies, potentially differentially regulating peptide
release, in part due to different sets of ATP receptors on axons
and cell bodies (Lemos et al., 2012).Neuron 76, October 4, 2012 ª2012 Elsevier Inc. 103
Figure 4. Micrograph Showing the Oxytocin Neurons of the
Hypothalamic Supraoptic Nucleus
Width of micrograph, 900 mm.
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lular stores, particularly the endoplasmic reticulum. Oxytocin,
or agents such as thapsigargin that induce calcium release
from intracellular stores into the cytoplasm, can directly evoke
dendritic release of oxytocin or vasopressin independent of
action potentials (Lambert et al., 1994; Ludwig et al., 2002).
Release of intracellular calcium can also prime the system for
enhanced release upon subsequent increases in electrical
activity (Ludwig et al., 2002; Ludwig and Leng, 2006). Oxytocin
receptor activation induces phospholipase C resulting in
production of IP3 and subsequent release of calcium from the
endoplasmic reticulum. This priming enhances the subsequent
release of oxytocin, potentially related to actin-dependent move-
ment of peptide-containing granules toward the plasma
membrane (Tobin and Ludwig, 2007; Leng et al., 2008). Priming
of oxytocin-laden DCVs, in part by movement of the DCVs to
a position closer to the plasma membrane, allows a substantial
amplification of oxytocin release with subsequent electrical
activity. Interestingly, priming with thapsigargin can increase
the K+-mediated depolarization-induced oxytocin release for
an extended period of 90 min (Ludwig et al., 2002). Priming of
DCV release has been studied outside the brain, particularly in
pituitary cells that synthesize luteinizing hormone; axonal release
of GnRH from preoptic neurons into the portal blood supply
of the median eminence primes the luteinizing hormone cells
by multiple mechanisms to show an enhanced release in re-
sponse to subsequent GnRH stimulation (Leng et al., 2008;
Fink, 1995).
Differential expression of proteins involved in exocytosis in
dendrites and axon terminals may also account for differences
in release. In magnocellular axon terminals in the neurohypoph-
ysis, VAMP-2, SNAP-25, and syntaxin-1 are found near oxytocin
and vasopressin-containing dense core vesicles; in contrast, the
dendrites of the same cell type contain syntaxin-1, but SNAP-25,
VAMP-2 and synaptotagmin-1 show no colocalization with
oxytocin or vasopressin (Tobin et al., 2012). Synthesis of neuro-
peptides generally occurs in the cell body, but has also been re-
ported in dendrites. Dendritic synthesis of neuromodulators
such as BDNF has been suggested as playing a critical role in
the development of cortical dendritic spines (Kaneko et al.,
2012), and in responses of hypothalamic neurons to leptin to
control energy homeostasis (Liao et al., 2012).
What function would a dendritically released neuropeptide
play? The most probable role would be that the neuropeptide
acts to signal other nearby neurons to either increase or104 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.decrease activity. In the olfactory bulb, most of the neurons,
including mitral, periglomerular, and granule cells possess
dendrites that release either GABA or glutamate at presynaptic
specializations (Shepherd et al., 2004). Many of the presynaptic
dendrites are organized in a reciprocal manner; for instance,
mitral cell dendritic release of glutamate activates a presynaptic
granule cell dendrite that releases GABA back onto the mitral
cell, resulting in feedback inhibition. In contrast, most dendrites
in the brain are not presynaptic to other cells, and dendritic
release of peptides appears to be independent of synaptic
specializations. Nonsynaptic release of oxytocin or vasopressin
could serve to recruit or inhibit neighboring cells, or to synchro-
nize activity. Oxytocin receptors are expressed by oxytocin
neurons (Freund-Mercier et al., 1994), and vasopressin recep-
tors by vasopressin cells (Hurbin et al., 2002). During lactation,
oxytocin is released in an orchestrated burst where many or
most oxytocin neurons fire rapidly for a brief period of about
a second (Armstrong and Hatton, 2006; Leng et al., 2008). Inter-
mittent bursts of oxytocin release may prevent oxytocin recep-
tors in the mammary gland from desensitizing if oxytocin levels
were to remain at statically raised levels. The burst of oxytocin
potentially appears to be dependent on dendritic release of
oxytocin that primes the cells for subsequent massive oxytocin
release induced by an increase in spike frequency, as described
above.
Dendritically released peptides can act to initiate retrograde
signals to modulate subsequent release of fast amino acid
neurotransmitters from local axons. Oxytocin released by mag-
nocellular cell bodies and dendrites reduces presynaptic gluta-
mate and GABA release; although this was initially thought to
be mediated by presynaptic peptide receptors, it appears
more likely that oxytocin release activates receptors on oxytocin
cells, resulting in release of an endocannabinoid that diffuses in
a retrograde direction to activate CB1 receptors on presynaptic
axons and thereby reducing fast transmitter release (Kombian
et al., 1997, 2002; Hirasawa et al., 2001, 2004; Leng et al.,
2008). Oxytocin release appears to be obligatory to achieve
this presynaptic inhibition after depolarization of oxytocin
neurons (Hirasawa et al., 2004). Blockade of synaptic activity
transiently isolates oxytocin cells from external influences,
potentially amplifying local cellular interactions. Here, the modu-
latory peptide that activates endocannabinoid secretion is
released from dendrites to inhibit nearby presynaptic axons;
a key feature of endocannabinoid modulation in many brain
regions is release from the postsynaptic neuron and retrograde
diffusion to modulate fast transmitter release from a presynaptic
axon, resulting in either short or long-lasting attenuation of GABA
or glutamate release by depression of presynaptic calcium,
increase in potassium conductance, or direct inhibition of vesicle
fusion (Lovinger, 2008). In vasopressin neurons, depolarization-
induced release of endocannabinoids also attenuated presyn-
aptic GABA synaptic activity by a calcium-dependent mecha-
nism; in addition, induced release of vasopressin reduced
IPSC frequency by a second cannabinoid-independent mecha-
nism (Wang and Armstrong, 2012).
Neurons in the preoptic/septal area synthesize GnRH. These
neuronsmay also release peptide from their dendrites to orches-
trate activity of other nearby GnRH neurons. Studies on fetal
Figure 5. Whole-Cell Recording of GABA-Mediated Synaptic
Currents Showing TRH Increases Frequency
TRH substantially increased the frequency of the IPSCs recorded in
GABAergic MCH neurons, which recovered after peptide washout. The
GABAA receptor antagonist bicuculline (BIC) blocked the synaptic currents.
TRH had no effect on miniature PSCs. Recordings were done in the presence
of AP5 and CNQX to block responses to synaptically released glutamate. The
recording pipette contained a high concentration of Cl, resulting in GABA-
mediated inward currents. From Zhang and van den Pol (2012).
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body and dendrites with increased activity, and suggested co-
localization of FM1-43 with GnRH immunoreactivity (Fuenzalida
et al., 2011); further corroboration with imaging of mature neuron
somatodendritic release from live GnRH cells would comple-
ment the histology.
The magnocellular neurosecretory neurons provide a good
model in which to study dendritic release of peptides, but as
with axonal release, these cells contain a substantially greater
number of peptide-containing DCVs, probably by a couple of
orders of magnitude, than other peptide- releasing neurons
that do not maintain a prominent projection to the median
eminence or neurohypophysis. That other neurons with more
modest expression of peptides follow the same model of
dendritic release is possible but merits further exploration.
Neuropeptide Modulation of GABA and Glutamate
Synaptic Actions
Most fast synaptic activity in the brain is due to synaptic release
of excitatory glutamate or inhibitory GABA or glycine. Modulation
of fast amino acid synaptic activity is a key target of CNS neuro-
peptides. Classically, signaling in regions of the brain such as the
hypothalamus involved in homeostatic regulation have been
seen as being based on direct peptidergic actions. A number
of early reviews on the transmitters of the hypothalamus either
ignored GABA and glutamate or included only a brief mention
of them. In contrast, signaling in higher regions of the brain
such as the hippocampus and cortex was seen primarily as
being based on GABA and glutamate transmission, with less
consideration of neuropeptide modulators. This dichotomy has
shown a strong convergence in recent years, with a greater
appreciation of fast transmitters in the more vegetative regions
of the brain, and more inclusion of neuropeptide modulation in
higher brain regions. Although peptide action in the CNS is notrestricted to modulation of fast synaptic activity, many actions
of peptides do alter GABA or glutamate signaling at post- or
presynaptic sites. For instance, Figure 5 shows an electrophys-
iological example of an excitatory peptide, TRH, that enhanced
the activity of local presynaptic GABA neurons, resulting in an
increased inhibition in GABAergic MCH neurons.
That peptides can play key roles in CNS function is shown in
experiments where genes coding for peptides were deleted.
Knocking out the POMC peptides resulted in an increase in
food intake and obesity, consistent with the view that these cells
play an anorexigenic role in energy homeostasis (Yaswen et al.,
1999); injections of alpha MSH agonists reversed the obesity.
Knockout of the MC4 receptor also results in obesity in rodents
(Huszar et al., 1997). In parallel, severe human obesity can be
caused by mutations in genes coding for POMC or its melano-
cortin receptors (Hager et al., 1998; Yeo et al., 2000; Krude
et al., 2003; Mencarelli et al., 2012).
An intriguing example of the importance of amino acid trans-
mitters in cells considered as primarily peptidergic is shown by
recent work on the inhibitory NPY/AgRP neuron. These cells
play a key orexigenic role in food intake. As noted above, injec-
tions of either NPY or AgRP into the hypothalamic area increase
food intake (Clark et al., 1984; Woods et al., 1998; Marsh et al.,
1998). Selective activation of the NPY/AgRP neuron with
DREADD (designer receptors exclusively activated by designer
drugs; Rogan and Roth, 2011) receptors increased feeding and
reduced energy expenditure (Krashes et al., 2011). Hunger and
ghrelin evoke a long-lasting increase in glutamatergic activity
to the AgRP neurons, and leptin reverses the increased activity
suggesting an on/off activation of glutamate input to AgRP
neurons is important in regulating activity and energy homeo-
stasis (Yang et al., 2011). In genetic knockout mice, various
neuroactive substances have been deleted from the NPY/
AgRP neuron. Surprisingly, the loss of NPY or its receptor, or
AgRP did not evoke a substantive change in feeding phenotype
(Palmiter et al., 1998; Qian et al., 2002; Erickson et al., 1996).
However, selective loss of AgRP/NPY neurons in the adult led
to a cessation of feeding and death (Luquet et al., 2005; Gropp
et al., 2005), suggesting that NPY and AgRP, while important
modulators of food intake, are only part of the transmitter puzzle
regulating energy homeostasis, and that other substances
released by the AgRP/NPY neurons are critical for survival, as
examined below.
The other piece of the transmitter puzzle synthesized by
AgRP/NPY neurons is GABA. Loss of GABA input to the parabra-
chial nucleus (PBN) appears to be essential for the severe drop in
food intake and death that results from ablation of the AgRP/NPY
neuron. Increasing GABA receptor activation in the PBN (Wu
et al., 2009), or reducing excitatory input to the PBN from the
nucleus of the solitary tract (Wu et al., 2012) both enhanced
food intake and survival. Suppression of glutamate excitation
in the PBN reversed starvation caused by AgRP/NPY neuron
ablation, and increased food intake in otherwise normal mice
(Wu et al., 2012). Together these data suggest that peptidergic
signaling in the AgRP/NPY cells plays a modulatory role in
food intake, but that the fast amino acid transmitter plays a key
role in some aspects of the function of these cells that cannot
be ignored.Neuron 76, October 4, 2012 ª2012 Elsevier Inc. 105
Figure 6. Presynaptic Neuropeptide Modulation of Fast Amino Acid
Transmitter Release
(A) A schematic representation of two axons both in synaptic contact with
a common dendrite.
(B) Release of neuropeptide from the bouton on the left diffuses laterally to the
other axon and enhances release of the fast amino acid transmitter.
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nucleus; in a complex series of experiments based in part on
selective optogenetic activation and inactivation, AgRP/NPY
axonal projections to oxytocin neurons were found to be critical
for stimulation of feeding elicited from activation of AgRP/NPY
cells. Both NPY and GABA inhibition of paraventricular oxytocin
cells contributed to the initiation of feeding (Atasoy et al., 2012);
the role of the GABA projection from the AgRP/NPY neuron to
the PBN was interpreted in the context of visceral malaise.
Another independent line of work has shown that knocking out
glutamate neurotransmission from SF1 neurons of the hypotha-
lamic ventromedial nucleus disturbs glucose regulation and
causes mice to suffer from hypoglycemia during fasting and to
have defective responses to insulin-induced hypoglycemia
(Tong et al., 2007).
Modulation of GABA and Glutamate Release by
Neuropeptides
One substantial mechanism underlying neuropeptide modifica-
tion of neuronal activity is the modulation of neurotransmitter
release by direct peptide actions on the axon terminal (Miller,
1998; Willis, 2006). Some peptides, for instance NPY (Colmers
et al., 1988), somatostatin (Lo´pez-Huerta et al., 2012; Tallent
and Siggins, 1997), and dynorphin, tend to reduce transmitter
release, whereas others such as hypocretin (van den Pol et al.,
1998) or glucagon-like peptide 1 (Acuna-Goycolea and van
den Pol, 2004) enhance release probability. Neuropeptide recep-
tors are found on both glutamate and GABA axon terminals
(Figure 6). In some regions of the brain, presynaptic modulation
has been suggested as the primary or only role of some neuro-
peptides. NPY, for instance, acts to a large degree by inhibiting106 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.neurotransmitter release from excitatory CA3 neurons in the
hippocampus; NPY had no detectable effect on either the active
or passive membrane properties of CA3 pyramidal neuron cell
bodies but reduced release of glutamate from axons of these
cells that terminated on CA1 pyramidal cells by a mechanism
based on reduction of calcium influx into the axon terminal
(Colmers et al., 1988). In the dentate gyrus, NPYY2 receptors ex-
pressed on axon terminals inhibited glutamate or GABA release,
and NPY Y1 receptors on granule cells mediated a cellular
inhibition (Sperk et al., 2007). Insight into a potential function of
hippocampal NPY is provided by NPY gene knockout (KO)
mice which maintained normal electrophysiological activity in
the hippocampus but showed poor recovery after induction of
limbic seizures with the glutamate agonist kainate, which caused
death in the majority of NPY-KO mice compared with little death
in normal mice treated with similar doses of kainate (Baraban
et al., 1997). Similarly, NPY Y5-receptor KO mice were also
more sensitive to kainate-induced seizures (Marsh et al.,
1999a). Together these data support the view that NPY may
function as an endogenous anticonvulsant, in part by attenuating
glutamate release.
In contrast to its presynaptic actions onCA3 axons, NPY acted
primarily on cellular Y1 receptors to inhibit basolateral amygdala
neurons by suppressing a hyperpolarization-activated depola-
rizing Ih current that is a mixed cation current (Giesbrecht
et al., 2010).
Activation of presynaptic axonal peptide receptors can alter
transmitter release in a number of ways: alter voltage-gated
calcium channels, change potassium channel conductance,
change the phosphorylation state of a channel or channel-
related protein, or alter the actions of proteins involved in vesicle
movement or membrane fusion. As examined above, calcium
plays a key role in transmitter/neuropeptide release, irrespective
of the release site. Activation of voltage-gated calcium channels
increases cytoplasmic calcium by influx from the extracellular
space and enhances neuropeptide release. Calcium release
from intracellular stores can also enhance neuropeptide release
(Shakiryanova et al., 2011), and can potentially be achieved in
the absence of membrane potential depolarization (Ludwig and
Leng, 2006).
Many examples of peptides that alter GABA or glutamate
release presynaptically by modulation of cytoplasmic calcium
exist. For instance, MCH reduces calcium influx through L, N,
and P/Q type calcium channels and presynaptically reduces
release of glutamate and GABA (Gao and van den Pol, 2001,
2002). In the suprachiasmatic nucleus (SCN), nociceptin (orpha-
nin FQ) acts presynaptically to reduce glutamate release from
the retinohypothalamic tract by a mechanism based on attenua-
tion of N-type calcium currents, and to a lesser degree P/Q type
calcium currents; because the retinal ganglion cells have been
eliminated by brain slice preparation, the peptide actions could
not have been on the glutamatergic cell body (Gompf et al.,
2005). Similarly, nociceptin acts presynaptically to reduce
GABA release in the central amygdala (Roberto and Siggins,
2006). Excitatory hippocampal mossy fibers release dynorphin,
which results in heterosynaptic inhibition of glutamate release
from other hippocampal mossy fibers, and inhibits hippocampal
long-term potentiation (LTP) (Weisskopf et al., 1993) and is
Figure 7. NPY Inhibits Glutamatergic Hypocretin Cells by Multiple
Mechanisms
NPY acts on Y1 postsynaptic receptors to inhibit the hypocretin cell, and acts
on Y2 presynaptic receptors to attenuate release of GABA and glutamate.
Different actions of NPY are shown by the red arrows, with a downward arrow
indicating a decrease, and upward arrow an increase. These NPY axons also
contain GABA. Based on Fu et al. (2004) and Horvath et al. (1999). NPY
probably has similar effect on many of its target neurons, including the POMC
cell (Cowley et al., 2001), although the subset of NPY receptors expressed in
cell bodies or terminals may differ from cell to cell.
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P calcium channel (Castillo et al., 1996). The long duration of
the dynorphin-induced effect on LTP was suggested to be due
to slow dynorphin clearance from the extracellular space.
Peptide release from an axon can potentially feed back on
the releasing axon to depress or enhance release of fast amino
acid transmitters. Mu opioid neuropeptides are released by
POMC neurons, and these peptides reduce release of fast amino
acid transmitters from POMC axons (Dicken et al., 2012).
Peptides released at a particular location can act at multiple
pre- and postsynaptic sites to modulate the activity of multiple
effectors. NPY acts pre- and postsynaptically to inhibit hypocre-
tin neurons and the axons that terminate on POMC neurons
(Figure 7; Fu et al., 2004). Hypocretin-2 enhances glutamate
release by presynaptic actions in the ventral tegmental area, a
region of the brain involved in reward and motivation, and also
potentiates NMDA receptor actions in the postsynaptic cell
through activation of protein kinase C (Borgland et al., 2008).
Peptides can modulate a number of different channels
or transporters that regulate neuronal activity and spike proba-
bility, including sodium channels, nonselective cation channels,
sodium-calcium exchangers, and voltage-dependent calcium
channels. Many inhibitory neuropeptides reduce GABA or gluta-
mate release by activating G protein-coupled inwardly rectifying
K+ (GIRK) channels, also called Kir3 channels. GIRK channels
have become increasingly recognized as playing important rolesin both normal brain processes, and in disease states (Lu¨scher
and Slesinger, 2010). Different GIRK channels arise from the het-
eromeric assembly of different subunits (Luja´n et al., 2009); after
Gi/Go activation, Gb and Gg bind to the GIRK channel, resulting
in hyperpolarization and inhibition. GPCR kinases can block
GPCR function by phosphorylation-mediated internalization of
the receptor; recent evidence suggests that the GPCR kinases
can also directly and rapidly inactivate GIRK channels by
competitively binding Gb and Gg subunits, thereby reducing
GIRK channel activity (Raveh et al., 2010). Neuropeptides that
inhibit neuronal activity by activating GIRK channels include
NPY, somatostatin, opioid neuropeptides including dynorphin
and met-enkephalin and others (Nakatsuka et al., 2008;
Nassirpour et al., 2010; Li and van den Pol, 2008). On the other
hand, excitatory neuropeptides such as substance P (Koike-
Tani et al., 2005) and hypocretin (Hoang et al., 2003) also act
on GIRK channels, but inhibit the GIRK current to increase
neuronal activity.
Coupling of receptors to ion channels may be different in
different processes of the same cell. For instance, mu opioid
receptors that respond to met-enkephalin and other related
opioid peptides often show fast desensitization of GIRK currents
(Williams et al., 2001). Mu opioid receptor responses desensitize
rapidly in the POMC cell body; in contrast, mu receptor
responses are resistant to desensitization in the context of
reducing GABA release from presynaptic axon terminals
synapsing with the recorded cell (Pennock et al., 2012).
Role of Colocalized Neuropeptides with Similar
or Opposing Neuronal Actions
Many neurons contain multiple neuropeptides (Ho¨kfelt et al.,
1986, 1990; Skofitsch et al., 1985; Zupanc, 1996). For example,
neurons of the hypothalamic arcuate nucleus that utilize the
catecholamine neuromodulator dopamine to inhibit prolactin
release from the adenohypophysis also employ the amino acid
transmitter GABA, and additionally synthesize a number of
different neuropeptides including neurotensin, galanin, growth
hormone releasing factor (GRF), met-enkephalin, leu-enkeph-
alin, and dynorphin (Everitt et al., 1986). Single cells utilizing
GABA and dopamine also contained galanin and either GRF or
neurotensin; whether single dopamine cells contain all the
peptides listed here remains to be determined. Synthesis of
multiple neuroactive agents is not restricted to the hypothal-
amus. Single hippocampal interneurons synthesize GABA, NPY,
and somatostatin, all with inhibitory actions. Neuropeptides are
sequestered in DCVs, whereas the fast amino acid transmitters
are found in small clear vesicles. Although we generally assume
that peptides cosynthesized by a neuron are also stored and
released from the same DCVs, there is limited evidence that
different DCVs in a single neuron may contain different concen-
trations of multiple peptides (Zupanc, 1996). For instance, vaso-
pressin and galanin have been reported to show differential
expression in different DCVs in the same cell (Landry et al.,
2003). Outside the brain, cells of the anterior pituitary synthesize
both luteinizing hormone and follicle cell stimulating hormone,
and there is evidence for differential regulation of synthesis
and release (Fink, 1995). One clear manner in which different
peptides can be released differentially by the same neuron isNeuron 76, October 4, 2012 ª2012 Elsevier Inc. 107
Figure 8. Dynorphin Attenuates Voltage-Gated Calcium Current
A command depolarization of a glutamatergic hypocretin neuron caused
a calcium influx (a). Dynorphin reduced the calcium current (b), which recov-
ered after peptide washout. Cd2+ completely blocked the current, consistent
with it being calcium-mediated. From Li and van den Pol (2006).
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different genes have different regulatory elements and respond
to different sets of transcription factors. Therefore, differential
synthesis, potentially in response to neuromodulators that alter
transcription of different genes selectively, may allow a change
in the proportion of released peptides over time.
Multiple Peptides with Similar Actions in Single Neurons
In some neurons, multiple active peptides are cleaved from the
same precursor. One example of this is proopiomelanocortin
which is cleaved by peptidases into a number of potentially
neuroactive peptides including beta-endorphin, a-MSH, g-MSH,
corticotropin, and others. POMC cells may also synthesize
galanin-like peptide and cocaine and amphetamine related tran-
script (CART); all of these peptides may modulate food intake
(Elmquist, 2001; Gundlach, 2002).
Colocalization of peptides with related functions, but with
independent synthetic pathways is also not uncommon.
Neurons in the hypothalamic arcuate nucleus that synthesize
NPY and AgRP are a good example of this. NPY exerts direct
inhibitory actions through a number of NPY receptors. AgRP is
thought to act in a less direct inhibitory manner, by blocking
the excitatory actions of POMC derived a-MSH on the MC4mel-
anocortin receptors (Cone, 2005), although actions of AgRP
independent of the MC4 receptor have also been described
(Marsh et al., 1999; Fu and van den Pol, 2008). Intrahypothalamic
application of either NPY or AgRP increases food intake, indi-
cating that both peptides play a positive role in energy homeo-
stasis (Schwartz et al., 2000; Seeley and Woods, 2003). Use of
multiple neuroactive peptides could enhance the response of
target cells expressing the multiple relevant receptors. Alter-
nately, one peptide could activate homotypic receptors on one
cell, and the second could activate relevant receptors on
a different target cell. Cosynthesized peptides are probably
also co-released.
Another mechanism of peptide collaboration is based on
competition for peptidases. For instance, the actions of sub-
stance P on EPSCs in the parabrachial nucleus were enhanced
by calcitonin gene related peptide (CGRP) by a mechanism108 Neuron 76, October 4, 2012 ª2012 Elsevier Inc.based on CGRP-mediated attenuation of the activity of extracel-
lular peptidases that inactivate substance P, apparently by
competition for the peptidases (Saleh et al., 1996). Furthermore,
use of the peptidase inhibitor phosphoramidon increased the
amplitude of the substance P effect by about ten-fold, suggest-
ing a normally rapid breakdown of substance P. The expression
and release of peptidases is another dimension of the regulation
of the half-life of neuropeptides that merits consideration relating
to the range of efficacy of peptide actions.
Opposing Peptides in Single Cells
From different precursor proteins, neurons may also synthesize
neuropeptides that can exert opposing actions at the cellular
level. Dynorphin is an opioid neuropeptide which acts at kappa
Gi/Go-coupled opioid receptors, leading to cellular inhibition
(Chavkin et al., 1982) by presynaptic inhibition, activation of K+
currents, or attenuation of voltage-gated calcium channels. An
electrophysiological example of dynorphin attenuation of cal-
ciumcurrent is shown in Figure 8. A number of different excitatory
neurons release this inhibitory peptide. Dynorphin is colocalized
with excitatory vasopressin in magnocellular neurosecretory
neurons, with excitatory hypocretin/orexin neurons in the lateral
hypothalamus, with excitatory kisspeptin and neurokinin B in
the arcuate nucleus (Goodman et al., 2007) and in glutamatergic
granule cells in the hippocampus (Simmons et al., 1995).
Hypothalamic hypocretin neurons are critical for cognitive
arousal and normal sleep and wake cycles in mammals, and
they also play a role in drug addiction. In humans, the loss of
hypocretin neurons results in the neurological syndrome narco-
lepsy, characterized by excessive day-time sleepiness (Burgess
and Scammell, 2012; Chemelli et al., 1999; Lin et al., 1999). In the
hypocretin-dynorphin neuron, both peptides are synthesized by
the same neurons in rodents and humans (Chou et al., 2001;
Crocker et al., 2005) and released, probably simultaneously (Li
and van den Pol, 2006), from long axons that terminate in a large
number of regions of the brain and spinal cord (Peyron et al.,
1998; van den Pol, 1999). Receptors for hypocretin (Sakurai
et al., 1998) and dynorphin (DePaoli et al., 1994) are expressed
widely through the CNS. Hypocretin plays an excitatory role
(de Lecea et al., 1998; van den Pol et al., 1998) through Gq
coupled receptors (Sakurai et al., 1998). In hypocretin-receptive
neurons, hypocretin depolarizes the membrane potential,
increases spike frequency, increases intracellular calcium, and
increases GABA or glutamate release presynaptically (van den
Pol et al., 1998, 2002; Li et al., 2002).Whywould a neuron release
neuromodulators of opposing actions? There are a number of
possibilities. One possibility is that at the site of release, cells
may express receptors for only one of the peptides, and there-
fore respond to only that peptide. Peptides with opposing
actions can also act synergistically. Hypocretin evokes a direct
excitation of arcuate nucleus NPY cells; dynorphin inhibits
GABA release onto NPY cells by acting on presynaptic opioid
receptors thereby reducing synaptic inhibition and facilitating
the excitatory direct actions of hypocretin (Li and van den Pol,
2006). Thus, the opposing peptides released from the same
axon act on different cells to synergistically increase activity of
one of the responding cells.
Differential desensitization could also play a role in the
response to opposing peptides in responding cells expressing
Figure 9. Inhibitory Dynorphin and Excitatory Hypocretin Are
Synthesized and Released Together but Evoke Opposing Actions
Serial application of dynorphin evokes an outward current (green) with an
amplitude that desensitizes and decreases substantially with repeated expo-
sure. Serial application of hypocretin evokes an inward current (red) with only
modest desensitization. Combined application of dynorphin + hypocretin
(orange) gives an initial outward current, then little current, and then an inward
current. Based on Li and van den Pol (2006).
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release, may favor one peptide, whereas more protracted
release, or a high level release, may ultimately favor the other
peptide. Repeated application of dynorphin to voltage-clamped
melanin concentrating hormone (MCH) cells resulted in substan-
tially attenuated second and third outward (inhibitory) currents;
in contrast, repeated application of hypocretin showed substan-
tially less attenuation of its evoked inward currents (Figure 9).
Repeated coapplication of dynorphin + hypocretin therefore re-
sulted in an initial outward (hyperpolarizing) current but shifted to
an inward current (depolarizing) with repeated coapplication (Li
and van den Pol, 2006). Thus, in this example, low levels of cor-
elease might favor a modest inhibition, whereas high levels of
corelease may ultimately favor excitation. A related possibility
is that two opposing peptides could act with different time
courses either due to different latencies or durations of action,
and therefore one peptide may truncate the effect of the other
primarily during the overlap of the two time courses. Here, I focus
on two opposing neuroactive substances; however, many cells
contain more. For instance, a recent paper found that channelr-
hodopsin-evoked glutamate release from hypocretin cells was
critical for controlling the activity of postsynaptic histamine neu-
rons (Scho¨ne et al., 2012).
Another role for opposing peptide signaling would be in
feedback regulation of release of peptides from the same or
neighboring release sites. In vasopressin neurosecretory cells,dynorphin is coreleased with vasopressin locally by the somato-
dendritic complex and serves a key role in feedback inhibition of
vasopressin cells (Brown and Bourque, 2004; Brown et al.,
2004), in part by inhibition of plateau potentials required for spike
bursts. In most brain regions, vasopressin acts via a Gq receptor
to excite neurons (Raggenbass, 2008). However, in vasopressin
neurons, vasopressin has been reported to exert a rapid inhibi-
tory action, whereas dynorphin shows a slower inhibitory action
resulting in a gradual inhibition during successive spikes of
a burst. Dynorphin expression is increased during periods of
dehydration and so continues to provide a feedback inhibition
even while spike frequency is increased to counter dehydration
effects by increasing vasopressin release (Scott et al., 2009).
Dynorphin also reduces transmitter release from presynaptic
glutamate axons (Iremonger and Bains, 2009). The dual effect
of direct inhibition of release from the parent cell or its similar
neighbors, and presynaptic reduction in excitatory transmitter
stimulation, serve a similar role allowing dynorphin to depress
activity by multiple converging mechanisms. Actions of dynor-
phin in attenuating hippocampal mossy fiber glutamate release
are discussed above.
Kisspeptin is synthesized by cells of themedial hypothalamus,
and the peptide modulates the activity of GnRH neurons and
regulates reproduction and onset of puberty (Kauffman et al.,
2007; Han et al., 2005). Mutations of the GPR54, the kisspeptin
receptor, block puberty and cause infertility in rodents and hu-
mans (Dungan et al., 2006; Smith and Clarke, 2007). Dynorphin
and neurokinin B colocalize with kisspeptin in many mammals
(Goodman et al., 2007); dynorphin is proposed to act back on
the releasing kisspeptin neurons to synchronize and shape
pulsatile release patterns of kisspeptin (Navarro et al., 2009; Wa-
kabayashi et al., 2010).
Astrocytes and Peptides
Although we generally think of neuroactive peptides as being
synthesized by and exerting effects on neurons, the focus of
this review, glial cells may also employ neuropeptide signaling
and express receptors for neuromodulators in the CNS (Azmitia
et al., 1996; Kimelberg, 1988; Tasker et al., 2012). For instance,
one class of olfactory ensheathing glia that accompanies the
olfactory nerve from the olfactory mucosa into the olfactory
bulb shows very high levels of NPY expression (Ubink et al.,
1994; Ubink and Ho¨kfelt, 2000); NPY may act here as a trophic
factor to promote olfactory receptor neuron maturation and
survival (Doyle et al., 2012). Schwann cell precursors also
express NPY, and this expression is lost during postnatal
development (Ubink and Ho¨kfelt, 2000). NPY may also be
released by astrocytes. Ramamoorthy and Whim (2008) em-
ployed NPY-bound red fluorescent protein to show glutamate-
agonist mediated NPY secretion from cortical astrocytes.
Astrocytes in many brain regions express functionally active
vasopressin receptors (Brinton et al., 1998; Jurzak et al., 1995;
Kozniewska and Romaniuk, 2008). Peptide-responsive astro-
cytes can show fairly rapid activity-dependent structural plas-
ticity which may allow a further dimension of modulation of
neuropeptide actions and diffusion (Miyata et al., 2001; Theodo-
sis et al., 2008), including potential selective restriction of
peptide diffusion from a release site. For instance, during periodsNeuron 76, October 4, 2012 ª2012 Elsevier Inc. 109
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Reviewof dehydration or lactation, astrocytic processes may retract to
reduce segregation of synaptic complexes in the paraventricular
and supraoptic nuclei, thereby increasing neuron to neuron
membrane apposition, and potentially enhancing diffusion of
neuropeptides away from release sites (Hatton et al., 1984; Oliet
et al., 2004; Tasker et al., 2012).
Conclusion
At the cellular level, peptides enhance or attenuate neuronal
activity by modulating the activity of a number of different ion
channels, and by increasing or decreasing GABA or glutamate
release by direct actions on peptide receptors on presynaptic
axons. There are many unanswered, or even unaddressed,
questions relating to peptide release and response throughout
the brain. A key question relates to the release and response
to neuropeptides in the majority of neurons that synthesize
moderate or small amounts of peptide; do these cells follow
in the footsteps of the magnocellular neurosecretory neurons
that synthesize large amounts of peptide and have been the
subject of intense scrutiny? Or do the neurons that synthesize
substantially more modest amounts of neuropeptide possess
a different subset of defining features of release and induced
response?
With many neurons containing fast transmitters in addition to
one (or more) slower neuromodulator peptides, many questions
arise as to the relative role and contribution of the different
neuroactive substances in single cell types, both froma perspec-
tive of ion channel regulation, and from a more global view of the
neuron’s general functional assignment in the brain. Where
a particular neuropeptide acts relative to its release site, both
at the cellular and subcellular peptide receptor level, is another
important question that, although difficult to address, will
provide a critical link to understand the role of neuropeptides
at a functional level.
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